Of utmost importance, increases in unsaturated TCN2 (APO-TCN2) have been reported in patients with active autoimmune diseases including systemic lupus erythematous (SLE), autoimmune hemolytic anemia, and dermatomyositis, with levels often correlating with disease activity (146–148). This evidence concerns the gene TCN2 and autoimmune hemolytic anemia.